HC Wainwright Initiates Coverage on Audentes Therapeutics (BOLD)

Stock analysts at HC Wainwright assumed coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report issued on Wednesday. The brokerage set a “buy” rating and a $37.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 19.47% from the stock’s previous close.

A number of other research analysts have also issued reports on BOLD. BidaskClub upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. BMO Capital Markets assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, December 5th. They set an “outperform” rating and a $35.00 target price on the stock. William Blair assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price on the stock. ValuEngine lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Raymond James Financial assumed coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Audentes Therapeutics has a consensus rating of “Buy” and a consensus price target of $29.38.

Shares of Audentes Therapeutics (NASDAQ:BOLD) traded down $0.05 during trading hours on Wednesday, hitting $30.97. 164,500 shares of the company’s stock were exchanged, compared to its average volume of 152,514. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.88). sell-side analysts expect that Audentes Therapeutics will post -3.52 earnings per share for the current year.

In related news, SVP David Nagler sold 3,750 shares of the stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $30.00, for a total transaction of $112,500.00. Following the sale, the senior vice president now owns 3,750 shares in the company, valued at approximately $112,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders have sold a total of 747,750 shares of company stock worth $21,112,750 in the last quarter. 47.30% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Redmile Group LLC lifted its stake in Audentes Therapeutics by 77.8% in the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after purchasing an additional 638,780 shares during the last quarter. Jennison Associates LLC lifted its stake in Audentes Therapeutics by 182.4% in the 2nd quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after purchasing an additional 546,617 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Audentes Therapeutics by 10.4% in the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after purchasing an additional 73,809 shares during the last quarter. Vanguard Group Inc. lifted its stake in Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after purchasing an additional 383,837 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Audentes Therapeutics by 31.5% in the 2nd quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after purchasing an additional 153,617 shares during the last quarter. Institutional investors and hedge funds own 78.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/22/hc-wainwright-initiates-coverage-on-audentes-therapeutics-bold.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit